Netsmart myUnity ® Receives CHAP Verification for Home Health
OVERLAND PARK, Kan.--(BUSINESS WIRE)-- Netsmart, a leading provider of healthcare solutions and software for post-acute care communities, announced that its myUnity electronic health record (EHR) platform has received the Community Health Accreditation Partner (CHAP) Verification for Home Health. CHAP is a recognized non-profit accrediting organization authorized by the Centers for Medicare & Medicaid Services (CMS). This verification demonstrates the Netsmart commitment to advancing the home health market, by delivering high-quality, compliant solutions that meet the needs of providers and patients alike.
CHAP Verification is more than a credential—it's a reflection of the Netsmart dedication to supporting agencies with solutions that meet the highest standards of care, compliance and quality.
CHAP Verification is more than a credential—it's a reflection of the Netsmart dedication to supporting agencies with solutions that meet the highest standards of care, compliance and quality. This verification reinforces the Netsmart commitment to help providers deliver care that exceeds nationally recognized benchmarks. By achieving CHAP Verification, Netsmart aims to give clients the confidence that they are equipped with technology aligned to best practices, built to strengthen trust with patients and families and designed to support success in value-based care. It's another step forward in the Netsmart mission to deliver reliable, standards-aligned tools that help agencies grow, thrive and lead in a competitive landscape.
To earn CHAP Verified status, Netsmart underwent an extensive survey process, confirming that myUnity demonstrates no barriers to compliance. Following this comprehensive evaluation, the platform was validated without requiring any modifications, showcasing its effectiveness and reliability.
'Agencies need flexible, innovative solutions to advance value-based care, and a certified EHR platform like myUnity is critical to achieving that,' said David Strocchia, SVP & GM of Provider Solutions at Netsmart. 'We are committed to providing solutions that make providers' work easier, more efficient and more meaningful, allowing clinicians and staff to focus on delivering the best outcomes for those they serve. This CHAP Verification is another testament to our dedication to support providers with reliable, standards-aligned technology that empowers them to excel in a competitive landscape.'
Purposefully built for post-acute care settings, the myUnity platform simplifies scheduling, clinical documentation, billing and care transitions, enabling home health agencies to deliver coordinated, high-quality care more efficiently. Its robust interoperability features and compliance tools support providers' efforts to improve outcomes and streamline operations across care settings. Additionally, myUnity is integrated with the Netsmart CareFabric ® platform to extend capabilities beyond the EHR in areas such as referral management, patient and family engagement, workforce management, collection automation and much more.
'Receiving verification for home health following their recent hospice care certification highlights the Netsmart commitment to delivering high-quality technology and supporting providers across the post-acute care continuum,' said CHAP COO Teresa Harbour. 'We congratulate Netsmart on their recent verifications and are proud to recognize their myUnity solution that continues to demonstrate a strong dedication to delivering optimal care and setting a new industry standard.'
As the post-acute care landscape evolves, CHAP-verified technology remains essential for agencies aiming for compliance and excellence. Following this verification, Netsmart plans to pursue CHAP Verified status for home care, palliative care and pediatric care.
About Community Health Accreditation Partner (CHAP)
CHAP is an independent, nonprofit organization accrediting providers of home and community-based care. Founded in 1965, CHAP was the first to recognize the need for and value of home and community-based care standards and verification. As a Centers for Medicare & Medicaid Services (CMS)–approved accrediting organization, CHAP surveys organizations providing home health, hospice, and home medical equipment services to establish if Medicare Conditions of Participation and DMEPOS Quality Standard are met and recommend certification to CMS. CHAP's purpose is to partner with organizations nationwide to advance quality in the delivery of care and services in the home and community.
About Netsmart
Netsmart is an industry-leading healthcare technology organization empowering providers to deliver value-based care to the individuals and communities they serve. The Netsmart CareFabric ® platform serves as a unified, connected framework of solutions and services for human services, post-acute, payer and public sector communities. Together with our clients and Marketplace vendors, we develop and deliver innovative technology, including electronic health records (EHRs), interoperability, analytics, augmented intelligence (AI), population health management and telehealth solutions and services that assist organizations in transforming the care they deliver. The result has helped make a positive impact on the lives of more than 147 million individuals.
For more than 55 years, Netsmart has helped provider organizations in their efforts to improve the health and wellbeing of the communities we collectively serve. To learn more, visit ntst.com and connect with us on LinkedIn, Facebook or X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
a day ago
- Health Line
How much does Farxiga cost with Medicare?
Farxiga can cost up to $600 without insurance, with costs varying by pharmacy and whether you choose the brand or the generic. With Medicare coverage, your out-of-pocket costs depend on your plan. Farxiga (dapagliflozin) is a medication for helping lower blood sugar levels and reduce the risk of heart and kidney issues for those with type 2 diabetes, heart failure, or chronic kidney disease. With Medicare, drug overage usually comes through a Medicare Part D or a Medicare Advantage Prescription Drug (MAPD) plan. But whether your plan covers Farxiga and how much the drug will cost after coverage depends on your plan. How much does Farxiga cost per month with Medicare? Depending on where you get it, the cost of Farxiga without insurance can be over $600. The generic version, dapagliflozin, still costs more than $400. Farxiga can be covered by Medicare Part D or a MAPD plan. However, whether this medication or its generic version is covered by your Medicare drug plan and how much the plan will cover depends on its specific list of covered drugs, called a formulary. Private insurers manage Medicare drug plans and will have a different list depending on the plan. In addition, keep in mind that Medicare drug plans also have a deductible, premium, and copay that can vary depending on the plan. In 2025, the national base beneficiary premium for Part D is $36.78. According to the Centers for Medicare & Medicaid Services (CMS), the average monthly premium for Medicare Advantage plans is $17. What tier is Farxiga on? Within your plan's formulary, the insurer will place Farxiga in a tier. Generally, the higher the tier, the more you'll pay as a copayment, with the generic version typically in a lower tier than the brand-name drug. Many Medicare drug plans should include Farxiga, though its tier will depend on your plan. If your plan doesn't include this drug, it may include an alternative and equally effective medication. Generally, Medicare drug plans must cover at least two drugs from the most commonly prescribed categories. If the plan includes it and classifies it in a higher tier, your insurer may require prior authorization for coverage, which could include Step Therapy. This means you'll be asked to try a different, equally effective, but more cost-effective medication first before Medicare will approve coverage for Farxiga. Takeaway Farxiga is a drug designed to help lower blood sugar levels and reduce the risk of heart and kidney issues for those with type 2 diabetes, heart failure, or chronic kidney disease. Without insurance, the cost of Farxiga can range from around $400 to $600, depending on the pharmacy and whether you choose the brand-name or generic version. Usually, Medicare drug coverage comes through a Medicare Part D plan. While your exact coverage and costs for Farxiga depend on the specifics of your plan, many Medicare plans should cover this medication. Plus, once Medicare's price negotiation agreement starts in 2026, the price with coverage should be more affordable. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Business Wire
a day ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
a day ago
- Business Wire
Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, following the close of trading on the New York Stock Exchange. Chemed also announced developments related to second quarter earnings and full year 2025 guidance. In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee. However, as of the most recent quarterly earnings update, VITAS internal projections showed that the Florida consolidated program would end the 2025 government fiscal year ending on September 30, 2025 (2025 Cap Year) with a Medicare Cap cushion. Actual Medicare admissions in both April and May 2025 in Florida were weaker than anticipated and lower than VITAS' internal projections. As a result, VITAS now projects a Medicare Cap revenue limitation for the 2025 Cap Year of $18 million to $25 million related to the Florida consolidated program, excluding Tallahassee. The above projection includes actual results through May. Actual June results, which show better admissions than projected through the first half of the month, and actual results in the third quarter could have a significant impact on this projection. Previous guidance for 2025 earnings did not include any Florida Medicare Cap. The source of the Medicare Cap in the Florida consolidated program relates to two factors. The first factor is the 'community access' program. While community access has provided for a higher-than-average ADC growth rate and revenue growth rate at VITAS over the past two years, it adds pressure to the Medicare Cap due to patients accessing hospice care earlier in their disease trajectory. The second factor is the rate differential between the nationally determined increase in the Medicare Cap per admission and the actual reimbursement increase in our Florida consolidated programs, excluding Tallahassee, for the 2025 Cap Year. Specifically, the Medicare Cap per admission amount increased 2.9% while the Florida consolidated program reimbursement increase was 5.2%. VITAS estimates this rate differential will negatively impact the Florida consolidated program's Medicare Cap calculation by approximately $25 million for the 2025 government fiscal year, accounting for most, if not all, of the total revenue limitation discussed above. On June 20, 2025, the State of Florida announced that VITAS has received a Certificate of Need (CON) to begin operating in Pinellas County, Florida. Pinellas is the most densely populated county in Florida and has a hospice utilization rate below the state average. There were approximately 8,600 Medicare admissions to existing hospice providers in Pinellas County in 2024. Entering Pinellas County represents a significant opportunity for VITAS in 2026 and beyond for both overall growth and Medicare Cap mitigation. Based on the new start locations in Florida, primarily Marion County and Pinellas County, combined with operational changes currently being made in the Florida programs, management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year. This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year. In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year. While less financially significant than the VITAS Medicare Cap situation, during the second quarter of 2025, Roto-Rooter began to experience unexpected weakness in its residential business' demand compared to internal projections. This weakness represents a break from the trends experienced in the first quarter of 2025. Preliminary results for commercial demand in the second quarter of 2025 continue to reflect improved trends but not enough to offset the lower residential demand. Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance. A full discussion of the analysis will be included with our second quarter 2025 release and related investor conference call. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 30, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website Participants may also register via teleconference at: Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates, Chemed's estimates of the effect of Medicare Cap on VITAS' revenues and future prospects, Chemed's expectations regarding VITAS' patient mix, VITAS's future prospects in Pinellas County, FL and Chemed's expectations regarding demand for Roter-Rooter's services. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed's control. Chemed's actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release are based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
